CVR number 33372221
Industry 86.9020 Other human health activities

HEDESKOV TERAPI ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  0.6% 0.6% 0.6% 0.6% 0.6%  
Bankruptcy risk  6.0% 4.3% 4.4% 3.7% 5.0%  
Credit score (0-100)  40 48 46 52 43  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  480 559 602 499 571  
EBITDA  52.0 113 130 20.8 101  
EBIT  52.0 113 130 20.8 101  
Pre-tax profit (PTP)  59.0 293.0 -169.3 116.8 -262.8  
Net earnings  59.0 230.0 -132.2 91.0 -293.0  
Pre-tax profit without non-rec. items  59.0 293 -169 117 -263  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  1,807 2,037 1,805 1,839 1,426  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,866 2,182 1,865 1,902 1,507  
Net Debt  -1,817 -2,139 -1,624 -1,460 -1,258  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  480 559 602 499 571  
Gross profit growth  9.3% 16.5% 7.7% -17.2% 14.6%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,866 2,182 1,865 1,902 1,507  
Balance sheet change%  -1.2% 16.9% -14.5% 2.0% -20.8%  
Added value  52.0 113.0 130.1 20.8 101.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  10.8% 20.2% 21.6% 4.2% 17.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.4% 14.8% 7.2% 6.3% 31.5%  
ROI %  3.5% 15.6% 7.6% 6.5% -16.1%  
ROE %  3.2% 12.0% -6.9% 5.0% -18.0%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  96.8% 93.4% 96.8% 97.0% 94.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -3,494.2% -1,892.9% -1,248.5% -7,005.1% -1,240.4%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 63,170,400.0% 228,200.0% 0.0%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  31.6 15.0 28.8 26.6 16.2  
Current Ratio  31.6 15.0 28.8 23.6 16.2  
Cash and cash equivalent  1,817.0 2,139.0 1,624.4 1,459.7 1,257.9  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,222.0 987.0 580.4 313.8 61.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  52 113 130 21 101  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  52 113 130 21 101  
EBIT / employee  52 113 130 21 101  
Net earnings / employee  59 230 -132 91 -293